Seagen's deal – covering a drug candidate called LAVA-1223 – is in preclinical development and is designed to target and activate gamma delta T-cells in the presence of EGFR-expressing tumour ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback